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Background. We aim to provide useful evidence about the association of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-
lymphocyte ratio (PLR) with idiopathic sudden sensorineural hearing loss (ISSNHL) and its possibility of emerging as a cheap,
reliable, and independent prognostic marker of ISSNHL. Methods. 348 patients diagnosed with ISSNHL were included in our
retrospective data analysis. Blood samples and the hearing assessments of the patients were carried out. Then, the patients were
divided into 2 groups as “recovered” and “unrecovered” according to their response to the treatment. Results. Both mean NLR and
PLR values of the ISSNHL patients were significantly higher than the control group (both𝑃 < 0.001).TheNLR value was 5.98±4.22
in the unrecovered group and 3.50±3.38 in the recovered group (𝑃 < 0.001). After adjustment in a binary logistic regressionmodel,
only NLR value was associated with the recovery of ISSNHL (𝑃 = 0.001). Discussion.We demonstrated for the first time that NLR
and PLR values were significantly high in ISSNHL patients. Also the NLR level might be taken into account as a novel potential
marker to predict the patients’ prognosis in terms of recovery.
1. Introduction
A common definition of idiopathic sudden sensorineural
hearing loss (ISSNHL) is a loss of greater than 30 dB in 3
contiguous frequencies in less than 3 days [1]. A number
of etiologies of ISSNHL have been proposed, including
viral infection, vascular disturbance, and immune-mediated
mechanisms. However, there is no conclusive evidence for
any particular hypothesis [2–4]. The cause of ISSNHL has
been focused on chronic inflammation recently [5]. Chronic
inflammation can cause microvascular injury and atherogen-
esis, which is increasing ischemic risk in a direct manner [6].
The recent remarkable observation has been that neutrophil-
to-lymphocyte ratio (NLR) has predictability as a marker in
cardiovascular diseases and is emerging as an independent
useful prognostic parameter in cardiovascular diseases [7].
And platelet-to-lymphocyte ratio (PLR) is associated with
poor prognosis in patients with a key role in atherosclerosis
and atherothrombosis in peripheral arterial occlusive disease
patients [8, 9]. Both increasing NLR and PLR values may
be risk factors for atherosclerosis as well as inflammation in
microvascular structures.
In this study, we aimed to investigate the association of
NLR and PLR with ISSNHL and to provide its usability of
emerging as a cheap, reliable, and independent prognostic
marker of ISSNHL, for the first time.
2. Materials and Methods
2.1. Subjects. We reviewed 1046 consecutive ISSNHL patients
treated in our department from 2009 to 2013 in our ret-
rospective data analysis. We defined ISSNHL as an acute
unilateral deafness, with an abrupt onset (generally within 3
days), of more than 30 dB hearing loss at three consecutive
frequencies [10]. Inclusion criteria for this study were as
follows: visitingwithin 1 week fromonset, no previous steroid
treatment, taking blood samples and pure tone hearing
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Table 1: Siegel’s criteria of hearing improvement.
Type Hearing recovery
I Completerecovery
Patients whose final hearing level is
better than 25 dB regardless of the size
of the gain
II Partialrecovery
Patients who show more than 15 dB of
gain and whose final hearing level is
between 25 and 45 dB
III Slightrecovery
Patients who show more than 15 dB of
gain and whose final hearing level is
poorer than 45 dB
IV Noimprovement
Patients who show less than 15 dB of
gain
tests at the first visit, and no abnormal findings causing
hearing loss on the MRI. Patients were excluded from the
study if they had any acute inflammation; infection; diabetes
mellitus; systemic hypertension; hyperlipidemia; coronary
artery disease; acute or chronic renal failure; chronic liver
disease; chronic obstructive pulmonary disease; connective
tissue disease; inflammatory bowel disease; and any otologic
disease such as chronic otitis media, otosclerosis, acoustic
trauma history, andMeniere’s disease. 348 of 1046were finally
enrolled in this study. All the patients were treated with
prednisone in the dose of 1mg/kg per day, with a progres-
sive dose reduction, maintained for at least 2 weeks with
dexamethasone injections intratympanically. To compare the
biomarker profile, 537 age- and sex-matched healthy people
with no hearing loss who came to our hospital for regular
health checkup were also included in the present study. All
of them have no acute inflammations or otologic diseases of
above criteria. The study was approved by the International
ReviewBoard (IRB) of theMedicalUniversity of Yeonsei (IRB
number 4-2013-0935).
2.2. Hematologic Examinations. Blood samples were tested
for all patients at the first visit to prevent adverse effects of the
steroid treatment in high risk patients like patients with DM,
CBC, and routine chemistry. NLR, PLR were calculated as a
simple ratio between the absolute neutrophil and the absolute
lymphocyte counts, the absolute platelet and the absolute
lymphocyte counts. An automated blood cell counter was
used for CBCmeasurements using Sysmex XE-2100 (Sysmex,
Kobe, Japan). All sampleswere run in duplicate, and themean
values were used for statistical analysis.
2.3. Auditory Evaluation. Pure tone thresholds were obtained
for air conduction at 250Hz, 500Hz, 1 kHz, 2 kHz, 4 kHz,
and 8 kHz and for bone conduction at 250Hz, 500Hz, 1 kHz,
2 kHz, and 4 kHz, respectively. Audiologic data were reported
by the recommended methods of the Hearing Committee of
the American Academy of Otolaryngology Head and Neck
Surgery. Patients were evaluated according to the recovery
that was seen in a maximum of about two months in the
follow-up period. PTA was done with responses of the
patients to the treatment being classified according to Siegel’s
[11, 12] criteria (Table 1). Then, the patients were divided into
2 groups as “recovered (complete + partial + slight)” and
“unrecovered (no improvement).”
2.4. Statistical Analyses. Power analysis was performed to
determine the extent to which the proposed sample size
would be adequate (effect size = 0.083, 𝛼-risk = 0.05, and
sample size = 357). Continuous variables were summarized
asmean ± standard deviation (SD) and comparisons between
continuous variables utilized the Student’s 𝑡-test. Categorical
variables were summarized as percentages of the group
total and comparisons between groups were analyzed using
either Fisher exact test or chi-square test where appropriate.
Assessment of the bivariate relationship between recovery
and each risk factor was performed using data from 348
patients. We further calculated odds ratios (OR) with 95%
confidence intervals (CI) for unrecovered ISSNHL-risk fac-
tors with a binary logistic regression model. This adjusted
for confounders and enabled determination of variables of
interest associated with increased risk of hearing disturbance.
All tests used a 𝑃 value of 0.05 as a threshold for significance.
All statistical analyses were performed using SPSS software
(PASW for Windows, Rel. 18.0.0. 2009; SPSS Inc., Chicago,
IL, USA).
3. Results
A total of 348 ISSNHL patients were included in the current
analysis. All the characteristics and laboratory data between
ISSNHL patients group and control group are outlined in
Table 2. Groups were similar in terms of age, sex, and body
mass index (BMI) (𝑃 > 0.05). Mean NLR was 4.48± 3.92 and
mean PLR was 169.25 ± 102.88 in the patients group. Both
mean NLR and PLR values of the patients were significantly
higher than the control group (both 𝑃 < 0.001). Though
glucose was elevated in the patients group (𝑃 < 0.001), which
was the result of random glucose test, the values in both
groups were under normal value.
ISSNHL patients were divided into two subgroups
according to whether their PTAs in the follow-up periods
would be recovered or not. When the recovered group
was compared with the unrecovered group, age, sex, BMI,
WBC, absolute neutrophil counts, absolutemonocyte counts,
platelet counts, BUN, Cr, and AST values were not signif-
icantly different between two groups (Table 3). Mean lym-
phocyte value was higher in the unrecovered group than in
recovered group (𝑃 = 0.014).TheNLRvaluewas 5.98±4.22 in
the unrecovered group and 3.50±3.38 in the recovered group
(𝑃 < 0.001). The PLR value was 200.88 ± 112.12 and 148.47 ±
90.77 (𝑃 < 0.001). Glucose value was also significantly
different in two groups (𝑃 < 0.001). Significant values were
used as variables in a binary logistic regression model to
evaluate these values as independent risk factors for recovery
of ISSNHL (Table 4). In this model lymphocyte, monocyte,
NLR, PLR, and glucose were additionally included. After
adjustment for those values, only NLR value was associated
with the recovery of ISSNHL (𝑃 = 0.001).
In initial PTAs when they took a pure tone analysis
at a first visit, we could see more high tone loss PTAs in
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Table 2: The demographic and clinical characteristics of the study
populations (patients and controls).
Variables Patients group(𝑛 = 348)
Control group
(𝑛 = 537) P value
Age (yr) 48.19 ± 15.22 48.22 ± 11.60 0.976
Sex (n)
Male 171 288 0.215
Female 177 249
BMI (kg/m2) 23.47 ± 3.09 23.33 ± 4.45 0.804
Hb (103/u) 14.50 ± 5.69 14.04 ± 1.45 0.074
WBC (103/u) 8.42 ± 2.93 5.84 ± 1.47 <0.001
Neutrophil (103/u) 7.15 ± 9.07 3.06 ± 1.25 <0.001
Lymphocyte (103/u) 2.27 ± 3.31 1.77 ± 0.53 0.005
Monocyte (103/u) 0.49 ± 0.76 0.31 ± 0.11 <0.001
NLR 4.48 ± 3.92 1.83 ± 0.87 <0.001
Platelet (103/u) 252.40 ± 60.07 238.64 ± 49.98 <0.001
PLR 169.25 ± 102.88 146.75 ± 55.14 <0.001
Glucose (mg/dL) 111.71 ± 36.75 97.73 ± 19.81 <0.001
BUN (mg/dL) 14.55 ± 4.50 14.71 ± 5.30 0.647
Cr (mg/dL) 1.11 ± 5.48 0.82 ± 0.23 0.229
AST (U/L) 20.45 ± 13.37 21.77 ± 7.68 0.062
ALT (U/L) 22.10 ± 17.41 22.26 ± 14.83 0.888
The data are given as the means ± standard deviation or numbers and
percentages; 𝑃 < 0.05 value was accepted as significant level and the
significant differences between the groups were shown in bold.
the unrecovered group than in the recovered group (Table 5).
In the unrecovered group, three frequencies of 2000, 4000,
and 8000Hz were significantly decreased, compared with the
recovered group, respectively (𝑃 = 0.038, 𝑃 < 0.001, and
𝑃 < 0.001). Although there were significant changes for PTAs
in all frequencies (all 𝑃 < 0.001), low tone (250, 500Hz) and
middle tone (1000, 2000Hz) showed remarkable recoveries at
the follow-up PTAs in the recovered group (Figure 1).
4. Discussion
The major finding of this study is that NLR and PLR values
were significantly higher in patients with ISSNHL than
the control group and might be involved as the values of
atherosclerosis in the pathogenesis of ISSNHL. The ISSNHL
is a common otologic emergency, presenting mostly as an
acute unilateral deafness with an abrupt onset and defined
as sensorineural hearing loss of at least 30 dB occurring
in at least 3 consecutive frequencies within 72 hours [1].
However, the exact etiopathogenesis of the ISSNHL is still
unclear. Microcirculatory failure, infectious, immunologic,
and inflammatory reasons have been hypothesized [3, 4].
According to the viral theory, ISSNHL is due to a herpes
simplex virus infection; however, no specific serological
profiles or response to antiviral treatment has been reported
[2]. An immune-mediated hypothesis also cannot explain
why impaired immunity and autoimmune causes are not
observed in every case [13].
Table 3: The demographic and clinical characteristics of the
recovered group and unrecovered group.
Variables
Recovered
group
(𝑛 = 210)
Unrecovered
group
(𝑛 = 138)
P value
Age (yr) 47.31 ± 15.34 49.53 ± 14.99 0.185
Sex (n)
Male 97 0.189 0.189
Female 113 74
BMI (kg/m2) 23.41 ± 2.36 23.56 ± 2.60 0.567
Hb (103/u) 14.07 ± 1.71 15.17 ± 8.77 0.076
WBC (103/u) 8.00 ± 2.86 10.82 ± 20.97 0.055
Neutrophil (103/u) 6.47 ± 8.31 8.19 ± 10.07 0.083
Lymphocyte (103/u) 2.62 ± 4.03 1.74 ± 1.57 0.014
Monocyte (103/u) 0.56 ± 0.95 0.39 ± 0.25 0.067
NLR 3.50 ± 3.38 5.98 ± 4.22 <0.001
Platelet (103/u) 252.74 ± 60.00 251.88 ± 60.38 0.896
PLR 148.47 ± 90.77 200.88 ± 112.12 <0.001
Glucose (mg/dL) 106.34 ± 27.28 119.87 ± 46.63 0.002
BUN (mg/dL) 14.25 ± 4.48 15.01 ± 4.50 0.122
Cr (mg/dL) 1.31 ± 7.05 0.81 ± 0.20 0.410
AST (U/L) 21.26 ± 15.51 19.22 ± 9.14 0.164
ALT (U/L) 23.21 ± 19.31 20.42 ± 13.95 0.119
The data are given as the means ± standard deviation or numbers and
percentages; 𝑃 < 0.05 value was accepted as significant level and the
significant differences between the groups were shown in bold.
Table 4: Adjusted risk factors between the recovered group and the
unrecovered group.
Variables Adjusted odds ratio (95% CI) P value
Lymphocyte (103/u) 1.012 (0.856–1.197) 0.887
Monocyte (103/u) 1.377 (0.558–3.400) 0.487
NLR 1.179 (1.069–1.299) 0.001
PLR 1.001 (0.997–1.004) 0.725
Glucose (mg/dL) 0.994 (0.987–1.000) 0.065
The factors were adjusted in a binary logistic regression model.
Interestingly, ISSNHL could also be the result of an
ear microcirculation alteration due to genetic prothrom-
botic susceptibility or cardiovascular risk factors such as
hypertension and diabetes [14, 15]. A higher blood viscosity
may determine damage in ear microcirculation that can
produce hearing loss [16, 17]. Ciccone et al. showed that
ISSHL seemed to be associated with vascular endothelial
dysfunction and preclinical atherosclerosis by calculating the
carotid intima-media thickness [18]. Capaccio et al. stud-
ies examined hypercoagulable genomic polymorphisms and
found statistically significant differences in patients suffering
from ISSNHL with and without documented cardiovascular
thrombotic disease [19]. WBC and its subtypes were found
as inflammatory markers in cardiovascular diseases [20].
NLR was defined as a novel potential marker to determine
inflammation in cardiac and noncardiac disorders; oncology;
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Table 5: Audiometric evaluation of the recovered group and the
unrecovered group at different frequencies.
Recovered group
(𝑛 = 210)
Unrecovered group
(𝑛 = 138) P value
Follow-up
periods (days) 16.26 ± 9.88 25.42 ± 12.54 <0.001
Initial PTA
250 (Hz) 51.88 ± 28.68 49.78 ± 34.57 0.555
500 (Hz) 58.26 ± 26.46 56.27 ± 32.94 0.552
1000 (Hz) 58.17 ± 29.98 59.64 ± 32.88 0.667
2000 (Hz) 51.36 ± 32.87 58.95 ± 33.64 0.038
4000 (Hz) 51.50 ± 33.68 66.41 ± 33.42 <0.001
8000 (Hz) 56.05 ± 34.55 79.35 ± 32.18 <0.001
Follow-up PTA
250 (Hz) 15.55 ± 14.93 36.97 ± 32.09 <0.001
500 (Hz) 17.83 ± 19.01 43.95 ± 31.26 <0.001
1000 (Hz) 20.50 ± 22.09 45.88 ± 31.25 <0.001
2000 (Hz) 20.93 ± 23.77 45.51 ± 31.01 <0.001
4000 (Hz) 28.55 ± 28.06 54.93 ± 30.17 <0.001
8000 (Hz) 38.89 ± 32.36 71.73 ± 29.85 <0.001
The data are given as the means ± standard deviation or numbers and
percentages; 𝑃 < 0.05 value was accepted as significant level and the
significant differences between the groups were shown in bold. PTA: pure
tone average.
cardiology (acute coronary syndromes, heart failure, and
coronary revascularization procedures); end-stage renal dis-
ease; and inflammatory diseases such asAlzheimer, ulcerative
colitis, and appendicitis [21, 22]. A higher NLR indicates a
higher level of inflammation [23]. The interrelation between
neutrophils and endothelium has been accused of causing
increased damage to the endothelium and reported by Ott
et al. to explain platelet adhesion in patients with unstable
angina [24].
Platelets play an important role in the progression of
atherosclerosis. An elevated platelet count leading to an
elevated PLR might therefore lead to an increase in vascular
endpoints. Gary et al. proved that an increased PLR is
significantly associated with patients at high risk for critical
limb ischemia (CLI) and other cardiovascular endpoints [8].
By means of NLR and PLR CLI patients with a high risk
for limb amputation during a five-year follow-up period
were discriminated from patients with a lower risk for limb
amputation during the same follow-up period [25]. NLR
and PLR can be easily calculated as the neutrophils-to-
lymphocytes ratio and platelets-to-lymphocytes ratio in the
peripheral blood and practical, inexpensive, and also valuable
as high-cost inflammatory markers including IL-6, IL-1b, IL-
8, and TNF-alpha.
In our data, 348 patients with ISSNHL had significantly
different values of NLR and PLR from the control group
of 537 healthy people which had been well matched (both
𝑃 < 0.001). Other values like WBC, neutrophil, lymphocyte,
monocyte, and glucose values were also seen significantly
in the patients group, comparing with the control group
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Figure 1: Audiometric evaluations of the recovered group and the
unrecovered group at different frequencies.
(all 𝑃 < 0.05). But neutrophil, lymphocyte, and monocyte
values could be increased according to increasedWBC value,
which was still under acceptable normal value and could
not be judged for an abnormal finding in the hematologic
examination in both groups. Although glucose between the
patients group and the control group was significantly differ-
ent, because we could not control the sugar test with fasting
glucose test for all patients and control group, we cannot be
sure the value as the important risk factor. On the other hand,
NLR and PLR values are more reliable risk factors because
both values were increased in the patients group despite of
increased lymphocyte counts. Some studies suggested the
optimal cut-off value for NLR and PLR; NLR > 3.95 and PLR
> 150 [8]. Our values of NLR and PLR between the patients
group and the control group satisfied these cut-off criteria.
The NLR values between the patients group and the control
groupwere 4.48±3.92 and 1.83±0.87, and the PLRvalueswere
169.25 ± 102.88 and 146.75 ± 55.14. This result may support
a hypothesis that systemic stress activates inflammation,
endothelial function is injured, impaired endotheliummakes
atherosclerosis represented by increasing NLR and PLR, and
ischemic changes result in ISSNHL. It is true that the NLR
and PLR can be related profoundly to ISSNHL.
To know prognostic factors for ISSNHL, we divided the
patients group according to the recovery into subgroups: the
recovered group and the unrecovered group.According to the
previous study byMasuda et al., neutrophil and inflammatory
markers levels were found higher in ISSNHL patients with
no recovery [3]. Ulu et al. also showed that NLR levels
were higher in patients without recovery [26]. In our study,
comparing the recovered group with the unrecovered group,
Disease Markers 5
lymphocyte, monocyte, NLR, PLR, and glucose values were
increased significantly for the unrecovered group (all 𝑃 <
0.05). We further calculated odds ratios (OR) with 95% con-
fidence intervals (CI) for unrecovered ISSNHL-risk factors
with a binary logistic regression model. After adjustment
for those values, only NLR value was associated strongly
with the recovery of ISSNHL and was an independent risk
factor for the improvement of PTAs later (𝑃 = 0.001). This
result may show that the NLR value is more reflective of a
prognosis of ISSNHL than the PLR value. PLR value could
affect occurrences of ISSNHL but could not be related to
the prognosis of ISSNHL. In the unrecovered group, the
hearing losses at the frequencies (2000, 4000, and 8000Hz)
of the initial PTAs were occurred significantly, comparing
to the recovery group (each 𝑃 = 0.038, 𝑃 < 0.001, and
𝑃 < 0.001). There were hearing gains at all frequencies of
the follow-up PTAs significantly in the recovered group that
had the higher NLR value. But the recoveries were not big
only at high frequencies (4000 and 8000Hz) because the
recovered patients had still difficulty for hearing at the high
frequencies. The hearings at high frequencies may be more
friable by vascular ischemic changes and be more difficult
to be restored from the prior damage, while that at low and
middle frequenciesmay be recoveredwell. If ISSNHLpatients
have a lowNLR value, theymay have a low tone loss tendency
of PTA and be easy to be recovered.
A major limit of our study is the retrospective study
that was considered. While a single baseline admission
complete blood count (CBC) sampling has the benefit of
being readily available, serial samplingmay potentially yield a
better analytical time point. For these reasons, new advanced,
controlled, and randomized trials should be performed to
establish and confirm our results. Nevertheless, with the large
homogenous control group (𝑛 = 537) and well designed
statistical data, we have suggested that NLR and PLR values
help clinicians as practical and reliable indicator for ISSNHL
patients in terms of the treatment and the predicting of the
prognosis.
5. Conclusions
In the present study, although assigning specific mechanisms
for the hearing loss of the ISSNHL patients are only specu-
lative, we demonstrated for the first time that NLR and PLR
valueswhich are related to atherosclerosis in ISSNHLpatients
were significantly high and that endothelial dysfunction
might play an important role in the physiopathology of
hearing loss by the means of microvascular disturbances
and inflammatory processes. Also the NLR level might be
taken into account as a novel potential marker to predict the
patients’ prognosis in terms of recovery. Further prospective
studies in this area will help to diagnosis more quickly and
develop new treatments for ISSNHL patients.
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